What Nextmune does

Nextmune is a science-driven specialty pet healthcare company that develops, manufactures, and commercializes diagnostics and therapeutic products for companion animals (dogs and cats) and horses, with a portfolio organized around four therapeutic areas: allergy, dermatology, otology, and specialized nutrition. Its core proprietary technology is the PAX (Pet Allergy Xplorer) serum-based diagnostic platform, which identifies allergen-specific IgE antibodies in dogs, cats, and horses to guide allergen-specific immunotherapy treatment planning; the portfolio also includes patented natural-origin topical lines (ATOP 7, PYOclean with biofilm-defense technology, Dermoscent Essential 6) and a range of grooming, ear care, dental, and nutritional supplement products. The company operates as a wholly-owned subsidiary of Nextmune Holdings BV, with Vimian Group AB (a publicly listed Swedish specialty animal-health platform) functioning as the primary operating entity, and it commercializes its products primarily through B2B sales into veterinary practices and B2C e-commerce to pet parents, supported by channel partnerships with Bova Australia and Bova UK and a multilingual digital presence across Europe, North America, and Australia.

Name

Nextmune

Legal name

Nextmune

Website

https://nextmune.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Nextmune is a specialty pet healthcare company that develops proprietary diagnostics (PAX serum allergy testing) and therapeutic products in allergy, dermatology, otology, and nutrition for companion animals and horses, selling primarily to veterinarians and pet parents across Europe, North America, and Australia as part of Sweden's Vimian Group.

Ownership category

akta.pro rank

Product category

Veterinary Specialty Pharmaceuticals

NAICS

Veterinary Services (541940)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071)

akta.pro primary industry

Dermatology & Allergy Drugs (HLAMAEAH)

akta.pro secondary industries

Veterinary Vaccines (Biologics) (HLAMAEAL), Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK), Allergy & Anti-Inflammatory Supplements (HLAMALAL)

Keywords

• Veterinary diagnostics
• Pet allergy testing
• Veterinary dermatology
• Animal health products
• Companion animal care

Headquarters

HQ city

High Wycombe

HQ country

United Kingdom

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Diagnostic Services and Products: Nextmune generates revenue through the sale of diagnostic tests (PAX allergy testing) and therapeutic products including prescription medications, OTC treatments, and specialty nutrition for companion animals and horses.
2. Specialty Dermatology and Allergy Treatments: Revenue from topical treatments, spot-ons, shampoos, mousses, sprays, and oral supplements for dermatology, otology, and nutrition applications in pets.
3. Acquisition Integration - Avacta Animal Health: Vimian Group (parent) acquired Avacta Animal Health in March 2022 for £0.9 million upfront with potential £1.4 million deferred payment, strengthening Nextmune's position in veterinary allergy diagnostics and treatments in UK and Europe.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Nextmune develops, manufactures, and distributes proprietary veterinary diagnostics (notably the PAX Pet Allergy Xplorer and PAX Horse Allergy Xplorer serum-based allergy tests) and a broad portfolio of prescription and OTC therapeutic products for companion animals and horses, including allergen-specific immunotherapy, Dermoscent and PYOclean topical dermatology lines, ear care solutions, and specialized nutritional supplements.

Product overview

Nextmune is a global provider of proprietary diagnostics, prescription and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals and horses. The company operates as part of Vimian Group and specializes in four core therapeutic areas: allergy (with PAX serum testing and immunotherapy), dermatology (with Dermoscent topical products including Atop-7, Essential 6, PYOclean, and BioBalm lines), otology (ear care with Otodine, Otoact, and related products), and specialized nutrition (with supplements for gut, liver, kidneys, and skin/coat health). The product portfolio includes diagnostic tests (PAX Allergy Xplorer for pets and horses), immunotherapy treatments, and a comprehensive range of topical treatments, grooming products, ear care solutions, dental products, and nutritional supplements distributed primarily in Europe and North America.

Differentiator

Problem solved

Functional benefit

Products and services

• PAX - Pet Allergy Xplorer Serum-based allergy test for dogs and cats that identifies allergen-specific IgE antibodies to guide allergy diagnosis and immunotherapy treatment planning; sold to veterinary practices.
• PAX - Horse Allergy Xplorer Serum-based allergy test for horses that identifies allergen-specific IgE antibodies to diagnose environmental and insect bite allergies; sold to equine veterinarians.
• Allergen-specific Immunotherapy Customized allergen-specific immunotherapy treatments for companion animals based on PAX test results, designed to address the underlying cause of environmental allergies.
• Dermoscent Atop-7 Product Line Comprehensive line of soothing and hydrating skincare products (shampoo, spot-on, mousse, spray, hydra cream, max hydra) with natural-origin ingredients for atopic, dry, or sensitive skin in dogs and cats; includes the patented ATOP 7 Spray technology.
• PYOclean Purifying Product Line Patented purifying shampoo, mousse, and spray products combining manuka and lavandin essential oils with honey, propolis, and N-acetylcysteine to combat bacterial and yeast biofilms in pets with skin infections.
• Dermoscent Essential 6 Spot-on solution of natural origin for skin and coat health maintenance in dogs, cats, and horses, supporting skin barrier function and reducing odors.
• Dermoscent BioBalm Organic-certified water-resistant balm for nourishing, protecting, and hydrating dry rough skin on paw pads, elbows, and calluses in companion animals and horses.
• Otodine Ear Cleansing Solution Ear cleaning solution for dogs and cats designed to maintain ear hygiene and remove excess wax.
• Otoact Ear Cleansing Solution Ear cleansing solution for pets for routine ear hygiene and maintenance.
• Peptivet Oto Gel Gel for ear cleaning and management in dogs and cats.
• Stomodine F Product for periodontal health and oral hygiene in companion animals.
• Epato Liver Support Supplement Nutritional supplement for liver support in dogs and cats.
• Direne Gut Health Supplement Nutritional supplement for gut health and diarrhea management in companion animals.
• Enteromicro Complex Probiotic supplement for gastrointestinal balance in dogs and cats.
• Dr. Baddaky Omega-3 Omega-3 fatty acid supplement for skin and coat health in dogs, cats, and horses.
• Uti-Zen Supplement for urinary tract and kidney support in dogs and cats.
• Cicafolia Skincare Gel-Serum Skincare gel-serum with smart patch effect that forms an invisible protective film to promote natural skin repair in superficial wounds, burns, and scratches in companion animals.
• Iryplus Eye Cleansing Solution
• Winterpad Paw Balm
• Derm-10 Wound Care Cream
• Clorexyderm 4% Antiseptic Shampoo
• Dermoscent Senior Spot-On
• Dermoscent AromaCalm Spot-On

Quantifiable outcome

• Early probiotic exposure in atopic dogs resulted in long-term clinical benefits with sustained reduction in CADESI scores even three years after discontinuation (study published in Veterinary Immunology and Immunopathology).

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Bova AustraliacoreChannel Partner/ Reseller/ DistributorStrategic distribution partnership with bova.vet for Australian market, offering Nextmune products including PAX allergy testing.
• Bova UKminorChannel Partner/ Reseller/ DistributorPartnership with Bova UK for compounded veterinary specials (magistral preparations) to complement Nextmune's standard product portfolio.
• Avacta Group PLCcoreStrategic or Co-development PartnerAcquired Avacta Animal Health veterinary allergy division in March 2022 for £0.9M upfront plus potential £1.4M deferred payments. The acquisition included laboratory operations and product reselling rights, strengthening Nextmune UK's allergy diagnostics capabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Bova Specials: Specialist veterinary compounding pharmacy and channel partner in Australia and the UK. Functions as both a competitor in compounded specials and a distribution partner for Nextmune, making it a relevant adjacent peer.

Others

• Phadia (Thermo Fisher Scientific): Operates the ImmunoCAP allergy diagnostics platform historically used in veterinary reference labs. Comparable as an allergy serology technology peer to Nextmune's PAX system.

Broad incumbents

• Virbac: Global animal health company with companion animal dermatology, otology, and nutrition products. Competes with Nextmune's Dermoscent, PYOclean, and ear care lines through similar vet-channel distribution.
• Elanco Animal Health: Large diversified animal health company with dermatology, parasiticide, and specialty products. Competes broadly with Nextmune across the companion animal portfolio and benefits from larger scale and vet relationships.
• Ceva Santé Animale: Global animal health company with a strong companion animal dermatology franchise (DOUXO line), directly comparable to Nextmune's Dermoscent, ATOP 7, and PYOclean product families.
• IDEXX Laboratories: Global leader in veterinary diagnostics, including allergy and serology testing. IDEXX competes most directly with Nextmune's PAX diagnostic franchise and benefits from deeper R&D and broader in-clinic lab placement.
• Zoetis: Largest global animal health company with a dermatology and allergy portfolio (e.g., APOQUEL, CYTOPOINT) plus diagnostics via Vetscan. Overlaps with Nextmune on immunotherapy and dermatology therapeutics for companion animals.
• Dechra Pharmaceuticals: Specialty veterinary pharma focused on companion animal endocrinology, dermatology, and critical care. Overlaps with Nextmune on prescription dermatology and supportive therapeutics sold through vet clinics.
• Vetoquinol: European-headquartered animal health company with companion animal dermatology, otology, and supplement ranges, competing directly with Nextmune's Dermoscent and ear care portfolios in the EU vet channel.

Direct peers

• Heska (Antech Diagnostics): Veterinary diagnostics and specialty products company, including allergy testing. Acquired by Mars-owned Antech, giving it strong in-clinic distribution — directly comparable to PAX in the allergy serology category.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nextmune-italy
• Instagraminstagram.com/nextmune_scandinavia
• Facebookfacebook.com/nextmune.nordics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nextmune